IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
FAIL · Does not pass the screen
37.66 USD
At the last full screen 2026-09-15
Screened 2026-09-15 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 37.66 against the desk's fair-value range, base estimate 51.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price37.66 USD
Fair value51.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-01Read Accumulation41.58-9.4% to today
2026-08-02Read Markup36.01+4.6% to today ✓
2026-07-02Read Accumulation28.98+30.0% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
IDEAYA Biosciences, Inc. holds its Markdown at $37.66. The statistical read favours the sellers, held for 270 days.
As held on the ledger · 2026-09-15
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 270 days
Price at the screen
$37.66
Valuation
N/A trailing · -9.19 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-0.08
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.52%
Below 33%
Interest-bearing debt is just 2.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
36.99%
Below 33%
Interest-bearing cash and securities are 37.0% of assets, above the one-third limit.
Fail
Receivables
10.71%
Below 49%
Money owed to the company is 10.7% of assets, under the 49% limit.
Pass
Revenue purity
20.86%
Below 5%
20.9% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-15 screen. The gold marker is the market price at the same screen. A 35.4% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus Strong Buy. The average target sits +35% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Precision cancer drugs meet heavy losses and thin data
A company racing to match the right tumour to the right pill sounds clever on paper, yet the balance sheet tells a different story. IDEAYA is still posting a 62 percent negative profit margin and negative 14 percent return on equity, with a forward price to earnings ratio that sits in negative territory because earnings have yet to appear. Our screen clears it on ethics, but the opportunity rating stays at none.
Fourteen analysts cluster around a 50 dollar target, yet that view rests on early stage assets whose commercial path remains unproven. Unknown competitive moat and ongoing cash burn leave little margin for the usual biotech setbacks such as trial delays or regulatory pushback.
The real risk sits in the classic early stage trap: a low multiple that simply reflects absent profits rather than any bargain. Currency, dilution and clinical failure could all widen the gap between today's price and any eventual payoff. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IDYA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 15.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52.
2026-08-02Markup · changed$36.01+24.3%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 24.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52.
2026-07-18Accumulation$28.98+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52.
2026-07-03Accumulation$28.98+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$28.98Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
